Scholarlink

Background <p>The effect of glucagon-like peptide-1 (GLP-1) receptor agonists-based therapies on cardiovascular and renal outcomes has not been systematically reviewed across baseline kidney function groups. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) with GLP-1 Receptor Agonists (RAs) in patients with and without chronic kidney disease (CKD).</p> Methods <p>We performed a PubMed/Medline search of randomized, placebo-controlled, event-driven outcome trials of GLP-1 RAs versus placebo in patients with and without diabetes from inception to January 2025. CKD was defined as an estimated glomerular filtration rate (eGFR) &lt; 60&#xa0;ml/min/1.73m2. The primary outcome was major adverse cardiovascular events (MACE). Secondary outcomes included hospitalization for heart failure, CKD progression, cardiovascular and all-cause mortality. The relative risk (RR) was estimated using a random-effects model.</p> Results <p>Nine RCTs were included with a total of 75,088 patients, including 17,568 with eGFR &lt; 60&#xa0;ml/min/1.73m2. Use of an GLP-1 RA in patients with CKD was associated with a lower incidence of MACE (RR 0.84; 95% CI 0.74–0.95; P 0.006) and of CKD progression (RR 0.85, 95% CI 0.77–0.94; P 0.002), compared with placebo. There was no differential treatment effect of GLP-1 RA on these endpoints by CKD status at baseline.</p> Conclusions <p>GLP-1 RAs offer substantial cardiovascular and renal protection in patients with CKD. These findings support their use in CKD patients and confirms that these therapies may be continued as kidney function declines.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of GLP-1 receptor agonist-based therapies on cardiovascular and renal outcomes in diabetic and non-diabetic patients with CKD

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月2日

查看全文
  • Aliona Siniukovich,
  • Christoforos K. Travlos,
  • Sarah Freedman,
  • Thomas A. Mavrakanas,
  • Karim Gariani

摘要

Background

The effect of glucagon-like peptide-1 (GLP-1) receptor agonists-based therapies on cardiovascular and renal outcomes has not been systematically reviewed across baseline kidney function groups. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) with GLP-1 Receptor Agonists (RAs) in patients with and without chronic kidney disease (CKD).

Methods

We performed a PubMed/Medline search of randomized, placebo-controlled, event-driven outcome trials of GLP-1 RAs versus placebo in patients with and without diabetes from inception to January 2025. CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2. The primary outcome was major adverse cardiovascular events (MACE). Secondary outcomes included hospitalization for heart failure, CKD progression, cardiovascular and all-cause mortality. The relative risk (RR) was estimated using a random-effects model.

Results

Nine RCTs were included with a total of 75,088 patients, including 17,568 with eGFR < 60 ml/min/1.73m2. Use of an GLP-1 RA in patients with CKD was associated with a lower incidence of MACE (RR 0.84; 95% CI 0.74–0.95; P 0.006) and of CKD progression (RR 0.85, 95% CI 0.77–0.94; P 0.002), compared with placebo. There was no differential treatment effect of GLP-1 RA on these endpoints by CKD status at baseline.

Conclusions

GLP-1 RAs offer substantial cardiovascular and renal protection in patients with CKD. These findings support their use in CKD patients and confirms that these therapies may be continued as kidney function declines.